0JDK.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0JDK.L in your mock portfolio yet.
The company is currently unprofitable, with a negative EPS of -2.30 and a correspondingly negative PE ratio, indicating ongoing losses and no clear earnings support for the stock. These metrics suggest Iovance is still in a heavy investment and development phase, typical for early-stage biotech, but they also highlight significant execution and financing risk. Without visible revenue traction or improving profitability ratios, fundamentals do not yet provide a strong underpinning for the share price.
Despite a 10.6% gain over the last month, the stock trades at $2.55, far below its 200-day moving average of $7.44, indicating a pronounced longer-term downtrend. The RSI at 52.59 is neutral, implying neither overbought nor oversold conditions and suggesting that the recent bounce has not yet reversed the broader negative trend. Overall, price action and technicals point to a weak longer-term setup with only a modest short-term recovery.
Website traffic is flat at about 22,339 monthly visitors with 0.0% month-over-month growth, suggesting no recent surge in external engagement or commercial interest. Job openings have fallen 30% month over month to 7 roles, which may signal cost control or a slowdown in expansion, both of which can be interpreted cautiously in a development-stage biotech. Social media presence is modest but stable, with slow follower growth on Twitter/X and a relatively larger LinkedIn base, pointing to steady but not accelerating stakeholder interest.
Overall, Iovance Biotherapeutics’ stock setup appears bearish: the company is unprofitable, trades far below its long-term moving average, and shows only a modest recent price rebound against a much weaker longer-term chart. Alternative data are largely neutral to slightly cautious, with flat web traffic and reduced hiring offsetting only modest social media growth. Until there is clear evidence of improving fundamentals, clinical or commercial inflection, or a sustained technical reversal, the risk/reward profile skews to the downside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: